Cheyuo et al. [27] demonstrated that intravenous administration of exogenous recombinant human MFG-E8 (rhMFG-E8) one hour after ischemia resulted in reduced infarct volume and improved neurological function at 24 and 48 h post-ischemia. This evidence concerns the gene MFGE8 and ischemia.